Columbia, Mo.-based University of Missouri Health Care has purchased the inventory of a Versailles, Mo.-based pharmacy that recently closed its doors, according to a Dec. 19 report from NBC affiliate KOMU.  

After the FDA reaffirmed the end of Zepbound's two-year shortage, drug companies have announced shortages for 32 presentations of seven medications. 

Becker's asked pharmacy executives from hospitals and health systems across the U.S. to share the areas they're focusing on for 2025.

Zepbound, Eli Lilly's weight loss medication, became the first FDA-approved drug for obstructive sleep apnea Dec. 20. 

Nearly three years after its launch, Mark Cuban Cost Plus Drug Co. now manufactures injectables in shortage, works with thousands of healthcare facilities, including pharmacies, hospitals, long-term care sites and clinics, and offers more than 2,000 discounted generics and about a dozen branded medicines. 

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the production of compounded versions of the drugs, Bloomberg reported Dec. 19. 

A surge of vaccine and countermeasure claims hit an HHS program during the COVID-19 pandemic, and only about 26% of those claims have been processed, according to a Dec. 18 federal report. 

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535. 

A study published Nov. 24 in Arthritis Care & Research highlighted serious health risks associated with the use of oral acetaminophen in adults over 60. 

Hershey, Pa.-based Penn State Health has named Sam Wetherill, PharmD, as its next vice president and chief pharmacy officer, effective Dec. 30. 

Hundreds of pharmacies are permanently closing their doors as consumer trends change and businesses succumb to financial pressures. 

The FDA has added a boxed warning to the labeling of Veozah, a medication used to treat hot flashes, highlighting a rare but serious risk of liver injury. 

Pharmacy benefit managers were paid by drugmakers, including Purdue Pharma, to keep opioid prescriptions flowing even as overdose deaths soared across the U.S., according to an investigation by The New York Times. 

An uptake of GLP-1 medications is coinciding with an increase in first-time diagnoses after 15 days of taking a GLP-1, according to findings from Truveta Research and Reuters. 

The FDA has granted fast track designation to two combination vaccine candidates that aim to protect adults 50 and older from both influenza and COVID-19, according to a Dec. 16 AJMC report. 

Shares of the three largest pharmacy benefit managers' parent companies took a hit Dec. 16, after President-elect Donald Trump vowed that his administration would work to "knock out the middlemen."

The rise of telehealth services offering weight loss drugs like Ozempic has sparked concern among health professionals, with experts warning that these easy-to-access treatments are exacerbating eating disorders, Bloomberg reported Dec. 16. 

In March, MultiCare Health System joined Mark Cuban Cost Plus Drug Co.'s Marketplace and accessed 125 generics at a discounted price. Between April and October, the partnership saved MultiCare $1 million. 

Sanofi filed a lawsuit against the Health Resources and Services Administration in federal court Dec. 16, challenging the agency's decision to potentially remove the company from the 340B Drug Pricing Program over the company's proposed credit model. 

The American Society of Health-System Pharmacists and the ASHP Foundation have released their 13th annual Pharmacy Forecast, a comprehensive guide designed to help pharmacy leaders navigate the evolving healthcare landscape.